FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Pharmaceutics / Equine Drug Transporters: A Mini-Review and Veterinary Persp...
Pharmaceutics2020; 12(11); 1064; doi: 10.3390/pharmaceutics12111064

Equine Drug Transporters: A Mini-Review and Veterinary Perspective.

Abstract: Xenobiotic transport proteins play an important role in determining drug disposition and pharmacokinetics. Our understanding of the role of these important proteins in humans and pre-clinical animal species has increased substantially over the past few decades, and has had an important impact on human medicine; however, veterinary medicine has not benefitted from the same quantity of research into drug transporters in species of veterinary interest. Differences in transporter expression cause difficulties in extrapolation of drug pharmacokinetic parameters between species, and lack of knowledge of species-specific transporter distribution and function can lead to drug-drug interactions and adverse effects. Horses are one species in which little is known about drug transport and transporter protein expression. The purpose of this mini-review is to stimulate interest in equine drug transport proteins and comparative transporter physiology.
Get Full Text
Publication Date: 2020-11-08 PubMed ID: 33171593PubMed Central: PMC7695171DOI: 10.3390/pharmaceutics12111064Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article delves into the role of xenobiotic transport proteins in drug distribution and pharmacokinetics among horses, and points out that this area of study has not received enough attention compared to human and other animal species.

Introduction and Background

  • Transport proteins responsible for xenobiotic substances have a major role in determining how drugs are distributed and metabolized, which impacts their pharmacokinetic behavior.
  • Over recent decades, substantial research has been conducted to understand their functioning in humans and other animals used in pre-clinical trials, but not so much for the species of veterinary interest including horses.

Challenges With Current Knowledge

  • The research highlights that extrapolating the pharmacokinetic behavior of drugs across species is challenging due to differences in the expression of these transport proteins.
  • A lack of knowledge regarding the distribution and function of such proteins for species-specific cases can lead to negative interactions of drugs and potential adverse effects.

Focus on Equine Species

  • The researchers articulate that there’s a notable gap in the understanding of drug transport and expression of transporter proteins, specifically in horses.
  • This review attempts to raise awareness and interest in the research concerning equine drug transport proteins and comparative transporter physiology.

Cite This Article

APA
Rosa B. (2020). Equine Drug Transporters: A Mini-Review and Veterinary Perspective. Pharmaceutics, 12(11), 1064. https://doi.org/10.3390/pharmaceutics12111064

Publication

Pharmaceutics
ISSN: 1999-4923
NlmUniqueID: 101534003
Country: Switzerland
Language: English
Volume: 12
Issue: 11
PII: 1064

Researcher Affiliations

Rosa, Brielle
  • Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, TRW 2D01, Calgary, Alberta T2N 4Z6, Canada.

Conflict of Interest Statement

The author declares no conflict of interest.

References

This article includes 129 references
  1. Mealey KL. Adverse drug reactions in veterinary patients associated with drug transporters.. Vet Clin North Am Small Anim Pract 2013 Sep;43(5):1067-78.
    doi: 10.1016/j.cvsm.2013.04.004pubmed: 23890239google scholar: lookup
  2. César-Razquin A, Girardi E, Yang M, Brehme M, Saez-Rodriguez J, Superti-Furga G. In silico Prioritization of Transporter-Drug Relationships From Drug Sensitivity Screens.. Front Pharmacol 2018;9:1011.
    doi: 10.3389/fphar.2018.01011pmc: PMC6137680pubmed: 30245630google scholar: lookup
  3. Daneman R, Prat A. The blood-brain barrier.. Cold Spring Harb Perspect Biol 2015 Jan 5;7(1):a020412.
    doi: 10.1101/cshperspect.a020412pmc: PMC4292164pubmed: 25561720google scholar: lookup
  4. Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters.. Br J Pharmacol 2019 Dec;176 Suppl 1(Suppl 1):S397-S493.
    doi: 10.1111/bph.14753pmc: PMC6844579pubmed: 31710713google scholar: lookup
  5. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions.. Mol Aspects Med 2013 Apr-Jun;34(2-3):413-35.
    doi: 10.1016/j.mam.2012.10.010pubmed: 23506881google scholar: lookup
  6. Pochini L, Scalise M, Galluccio M, Indiveri C. OCTN cation transporters in health and disease: role as drug targets and assay development.. J Biomol Screen 2013 Sep;18(8):851-67.
    doi: 10.1177/1087057113493006pubmed: 23771822google scholar: lookup
  7. Orelle C, Mathieu K, Jault JM. Multidrug ABC transporters in bacteria.. Res Microbiol 2019 Nov-Dec;170(8):381-391.
    doi: 10.1016/j.resmic.2019.06.001pubmed: 31251973google scholar: lookup
  8. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer.. Nat Rev Cancer 2018 Jul;18(7):452-464.
    doi: 10.1038/s41568-018-0005-8pmc: PMC6622180pubmed: 29643473google scholar: lookup
  9. Khojasteh S.C.H., Cornelis E.C.A., Wong H. Drug Metabolism and Pharmacokinetics Quick Guide. Springer; New York, NY, USA: 2011.
  10. Lin W, Flarakos J, Du Y, Hu W, He H, Mangold J, Tanaka SK, Villano S. Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.. Antimicrob Agents Chemother 2017 Jan;61(1).
    doi: 10.1128/AAC.01784-16pmc: PMC5192155pubmed: 27821446google scholar: lookup
  11. Li J, Zhou S, Huynh H, Chan E. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.. Pharm Res 2005 Mar;22(3):397-404.
    doi: 10.1007/s11095-004-1877-8pubmed: 15835745google scholar: lookup
  12. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview.. Adv Drug Deliv Rev 2013 Oct;65(10):1340-56.
    doi: 10.1016/j.addr.2012.09.042pubmed: 23041352google scholar: lookup
  13. Oswald S. Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine.. Pharmacol Ther 2019 Mar;195:39-53.
    doi: 10.1016/j.pharmthera.2018.10.007pubmed: 30347208google scholar: lookup
  14. Boll M, Markovich D, Weber WM, Korte H, Daniel H, Murer H. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, beta-lactam antibiotics and ACE-inhibitors.. Pflugers Arch 1994 Nov;429(1):146-9.
    doi: 10.1007/BF02584043pubmed: 7708476google scholar: lookup
  15. Wenzel U, Thwaites DT, Daniel H. Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter.. Br J Pharmacol 1995 Dec;116(7):3021-7.
    doi: 10.1111/j.1476-5381.1995.tb15958.xpmc: PMC1909205pubmed: 8680738google scholar: lookup
  16. Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.. Curr Drug Targets 2011 May;12(5):600-20.
    doi: 10.2174/138945011795378504pubmed: 21039335google scholar: lookup
  17. Jetter A, Kullak-Ublick GA. Drugs and hepatic transporters: A review.. Pharmacol Res 2020 Apr;154:104234.
    doi: 10.1016/j.phrs.2019.04.018pubmed: 31004787google scholar: lookup
  18. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans.. Expert Opin Drug Metab Toxicol 2013 Mar;9(3):237-52.
    doi: 10.1517/17425255.2013.741589pubmed: 23256482google scholar: lookup
  19. Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics.. Drug Metab Dispos 2019 Aug;47(8):802-808.
    doi: 10.1124/dmd.119.086579pubmed: 31123036google scholar: lookup
  20. Arimori K, Nakano M. Drug exsorption from blood into the gastrointestinal tract.. Pharm Res 1998 Mar;15(3):371-6.
    doi: 10.1023/A:1011959828103pubmed: 9563065google scholar: lookup
  21. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.. Br J Pharmacol 1996 Nov;119(5):1038-44.
    doi: 10.1111/j.1476-5381.1996.tb15775.xpmc: PMC1915939pubmed: 8922756google scholar: lookup
  22. Ramirez CJ, Minch JD, Gay JM, Lahmers SM, Guerra DJ, Haldorson GJ, Schneider T, Mealey KL. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats.. Pharmacogenet Genomics 2011 Feb;21(2):66-75.
    doi: 10.1097/FPC.0b013e3283425f44pubmed: 21150813google scholar: lookup
  23. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.. Clin Pharmacokinet 2007;46(12):1039-49.
    doi: 10.2165/00003088-200746120-00004pubmed: 18027988google scholar: lookup
  24. Liao M, Zhu Q, Zhu A, Gemski C, Ma B, Guan E, Li AP, Xiao G, Xia CQ. Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans.. Xenobiotica 2019 Jul;49(7):852-862.
    doi: 10.1080/00498254.2018.1512017pubmed: 30132394google scholar: lookup
  25. Thamm D, Dow S. How companion animals contribute to the fight against cancer in humans.. Vet Ital 2009 Jan-Mar;45(1):111-20.
    pubmed: 20391394
  26. Gallegos RP, Nockel PJ, Rivard AL, Bianco RW. The current state of in-vivo pre-clinical animal models for heart valve evaluation.. J Heart Valve Dis 2005 May;14(3):423-32.
    pubmed: 15974538
  27. Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches.. J Alzheimers Dis 2008 Dec;15(4):685-707.
    doi: 10.3233/JAD-2008-15413pubmed: 19096165google scholar: lookup
  28. Lindner S, Halwachs S, Wassermann L, Honscha W. Expression and subcellular localization of efflux transporter ABCG2/BCRP in important tissue barriers of lactating dairy cows, sheep and goats.. J Vet Pharmacol Ther 2013 Dec;36(6):562-70.
    doi: 10.1111/jvp.12045pubmed: 23473424google scholar: lookup
  29. Pulido MM, Molina AJ, Merino G, Mendoza G, Prieto JG, Alvarez AI. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep.. J Vet Pharmacol Ther 2006 Aug;29(4):279-87.
    doi: 10.1111/j.1365-2885.2006.00744.xpubmed: 16846465google scholar: lookup
  30. Scarth JP, Teale P, Kuuranne T. Drug metabolism in the horse: a review.. Drug Test Anal 2011 Jan;3(1):19-53.
    doi: 10.1002/dta.174pubmed: 20967889google scholar: lookup
  31. Davis JL, Little D, Blikslager AT, Papich MG. Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation.. J Vet Pharmacol Ther 2006 Oct;29(5):379-85.
    doi: 10.1111/j.1365-2885.2006.00757.xpubmed: 16958782google scholar: lookup
  32. Serpa PBS, Brooks MB, Divers T, Ness S, Birschmann I, Papich MG, Stokol T. Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration.. Front Vet Sci 2018;5:304.
    doi: 10.3389/fvets.2018.00304pmc: PMC6288471pubmed: 30564584google scholar: lookup
  33. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG. Characterization of efflux transporters involved in distribution and disposition of apixaban.. Drug Metab Dispos 2013 Apr;41(4):827-35.
    doi: 10.1124/dmd.112.050260pubmed: 23382458google scholar: lookup
  34. Linardi RL, Stokes AM, Andrews FM. The effect of P-glycoprotein on methadone hydrochloride flux in equine intestinal mucosa.. J Vet Pharmacol Ther 2013 Feb;36(1):43-50.
    doi: 10.1111/j.1365-2885.2012.01390.xpubmed: 22428876google scholar: lookup
  35. Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, Xin B, Luettgen JM, Wong PC. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.. J Thromb Thrombolysis 2010 Jan;29(1):70-80.
    doi: 10.1007/s11239-009-0401-8pubmed: 19851712google scholar: lookup
  36. Pochini L, Galluccio M, Scalise M, Console L, Indiveri C. OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics.. SLAS Discov 2019 Feb;24(2):89-110.
    doi: 10.1177/2472555218812821pubmed: 30523710google scholar: lookup
  37. Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal Drug Transporters and Drug Interactions.. Clin Pharmacokinet 2017 Aug;56(8):825-892.
    doi: 10.1007/s40262-017-0506-8pubmed: 28210973google scholar: lookup
  38. Badée J, Achour B, Rostami-Hodjegan A, Galetin A. Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue.. Drug Metab Dispos 2015 Apr;43(4):424-32.
    doi: 10.1124/dmd.114.062034pubmed: 25564656google scholar: lookup
  39. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.. Biopharm Drug Dispos 2013 Jan;34(1):45-78.
    doi: 10.1002/bdd.1823pubmed: 23115084google scholar: lookup
  40. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.. Am J Physiol Gastrointest Liver Physiol 2000 Jan;278(1):G156-64.
    doi: 10.1152/ajpgi.2000.278.1.G156pubmed: 10644574google scholar: lookup
  41. Székely V, Patik I, Ungvári O, Telbisz Á, Szakács G, Bakos É, Özvegy-Laczka C. Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions.. Eur J Pharm Sci 2020 Aug 1;151:105395.
    doi: 10.1016/j.ejps.2020.105395pubmed: 32473861google scholar: lookup
  42. Hestand MS, Kalbfleisch TS, Coleman SJ, Zeng Z, Liu J, Orlando L, MacLeod JN. Annotation of the Protein Coding Regions of the Equine Genome.. PLoS One 2015;10(6):e0124375.
    doi: 10.1371/journal.pone.0124375pmc: PMC4481266pubmed: 26107351google scholar: lookup
  43. Gui C, Hagenbuch B. Cloning/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classification of the canine OATP/SLCO members.. Comp Biochem Physiol C Toxicol Pharmacol 2010 Apr;151(3):393-9.
    doi: 10.1016/j.cbpc.2010.01.005pmc: PMC2822128pubmed: 20079461google scholar: lookup
  44. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.. Pflugers Arch 2004 Feb;447(5):653-65.
    doi: 10.1007/s00424-003-1168-ypubmed: 14579113google scholar: lookup
  45. Ogura K, Choudhuri S, Klaassen CD. Full-length cDNA cloning and genomic organization of the mouse liver-specific organic anion transporter-1 (lst-1).. Biochem Biophys Res Commun 2000 Jun 7;272(2):563-70.
    doi: 10.1006/bbrc.2000.2830pubmed: 10833452google scholar: lookup
  46. Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, Feng B. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.. Clin Pharmacol Ther 2013 Jul;94(1):113-25.
    doi: 10.1038/clpt.2013.77pubmed: 23588318google scholar: lookup
  47. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.. J Pharmacol Exp Ther 2004 Oct;311(1):228-36.
    pubmed: 15194707doi: 10.1124/jpet.104.068536google scholar: lookup
  48. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin.. Clin Pharmacol Ther 2002 Dec;72(6):685-91.
    doi: 10.1067/mcp.2002.128469pubmed: 12496749google scholar: lookup
  49. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.. Biochem Biophys Res Commun 2000 Jun 24;273(1):251-60.
    doi: 10.1006/bbrc.2000.2922pubmed: 10873595google scholar: lookup
  50. Brown KA, Bouchard N, Lussier JG, Sirois J. Down-regulation of messenger ribonucleic acid encoding an importer of sulfoconjugated steroids during human chorionic gonadotropin-induced follicular luteinization in vivo.. J Steroid Biochem Mol Biol 2007 Jan;103(1):10-9.
    doi: 10.1016/j.jsbmb.2006.07.005pubmed: 17049229google scholar: lookup
  51. Drozdzik M, Gröer C, Penski J, Lapczuk J, Ostrowski M, Lai Y, Prasad B, Unadkat JD, Siegmund W, Oswald S. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine.. Mol Pharm 2014 Oct 6;11(10):3547-55.
    doi: 10.1021/mp500330ypubmed: 25158075google scholar: lookup
  52. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.. J Pharmacol Exp Ther 2004 Feb;308(2):438-45.
    doi: 10.1124/jpet.103.060194pubmed: 14610227google scholar: lookup
  53. Keiser M, Kaltheuner L, Wildberg C, Müller J, Grube M, Partecke LI, Heidecke CD, Oswald S. The Organic Anion-Transporting Peptide 2B1 Is Localized in the Basolateral Membrane of the Human Jejunum and Caco-2 Monolayers.. J Pharm Sci 2017 Sep;106(9):2657-2663.
    doi: 10.1016/j.xphs.2017.04.001pubmed: 28408210google scholar: lookup
  54. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.. Drug Metab Dispos 1999 Aug;27(8):866-71.
    pubmed: 10421612
  55. Olsén L, Ingvast-Larsson C, Larsson P, Broström H, Bondesson U, Sundqvist M, Tjälve H. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment.. J Vet Pharmacol Ther 2006 Apr;29(2):129-35.
    doi: 10.1111/j.1365-2885.2006.00724.xpubmed: 16515667google scholar: lookup
  56. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans.. Clin Pharmacol Ther 2007 Mar;81(3):362-70.
    doi: 10.1038/sj.clpt.6100056pubmed: 17215845google scholar: lookup
  57. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.. Clin Pharmacol Ther 2005 Mar;77(3):170-7.
    doi: 10.1016/j.clpt.2004.10.005pubmed: 15735611google scholar: lookup
  58. Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats.. J Pharm Sci 2005 Feb;94(2):233-9.
    doi: 10.1002/jps.20231pubmed: 15570603google scholar: lookup
  59. Oswald S, Müller J, Neugebauer U, Schröter R, Herrmann E, Pavenstädt H, Ciarimboli G. Protein Abundance of Clinically Relevant Drug Transporters in The Human Kidneys.. Int J Mol Sci 2019 Oct 24;20(21).
    doi: 10.3390/ijms20215303pmc: PMC6862022pubmed: 31653114google scholar: lookup
  60. BURNELL JM, KIRBY WM. Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations.. J Clin Invest 1951 Jul;30(7):697-700.
    doi: 10.1172/JCI102482pmc: PMC436299pubmed: 14850548google scholar: lookup
  61. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction.. Clin Nephrol 2009 May;71(5):567-70.
    doi: 10.5414/CNP71567pubmed: 19473619google scholar: lookup
  62. Schmitz DG. Toxins affecting the urinary system.. Vet Clin North Am Equine Pract 2007 Dec;23(3):677-90, vii.
    doi: 10.1016/j.cveq.2007.09.001pubmed: 18061857google scholar: lookup
  63. Gai Z, Visentin M, Hiller C, Krajnc E, Li T, Zhen J, Kullak-Ublick GA. Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.. Antimicrob Agents Chemother 2016 Sep;60(9):5573-80.
    doi: 10.1128/AAC.00907-16pmc: PMC4997869pubmed: 27401566google scholar: lookup
  64. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs.. Pharm Res 2009 Sep;26(9):2039-54.
    doi: 10.1007/s11095-009-9924-0pmc: PMC2719753pubmed: 19568696google scholar: lookup
  65. Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer.. J Vet Intern Med 2015 Jan;29(1):1-6.
    doi: 10.1111/jvim.12525pmc: PMC4858061pubmed: 25619511google scholar: lookup
  66. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.. J Pharmacol Exp Ther 1999 Jan;288(1):171-8.
    pubmed: 9862768
  67. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.. J Clin Invest 1995 Oct;96(4):1698-705.
    doi: 10.1172/JCI118214pmc: PMC185805pubmed: 7560060google scholar: lookup
  68. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.. Cell 1994 May 20;77(4):491-502.
    doi: 10.1016/0092-8674(94)90212-7pubmed: 7910522google scholar: lookup
  69. Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells.. J Biol Chem 1993 Jul 25;268(21):16059-64.
    pubmed: 8101846
  70. Kavallaris M, Madafiglio J, Norris MD, Haber M. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.. Biochem Biophys Res Commun 1993 Jan 15;190(1):79-85.
    doi: 10.1006/bbrc.1993.1013pubmed: 8093660google scholar: lookup
  71. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.. Proc Natl Acad Sci U S A 1996 Apr 30;93(9):4001-5.
    doi: 10.1073/pnas.93.9.4001pmc: PMC39475pubmed: 8633005google scholar: lookup
  72. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.. Eur J Pharmacol 1998 Oct 9;358(3):289-94.
    doi: 10.1016/S0014-2999(98)00607-4pubmed: 9822896google scholar: lookup
  73. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.. Antimicrob Agents Chemother 2004 Mar;48(3):809-14.
    doi: 10.1128/AAC.48.3.809-814.2004pmc: PMC353093pubmed: 14982769google scholar: lookup
  74. Fohner AE, Sparreboom A, Altman RB, Klein TE. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.. Pharmacogenet Genomics 2017 Apr;27(4):164-167.
    doi: 10.1097/FPC.0000000000000270pmc: PMC5346035pubmed: 28146011google scholar: lookup
  75. Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?. Pharm Res 2002 Apr;19(4):457-62.
    doi: 10.1023/A:1015191511817pubmed: 12033380google scholar: lookup
  76. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.. J Pharmacol Exp Ther 2001 Mar;296(3):723-35.
    pubmed: 11181899
  77. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.. Neuropharmacology 2007 Feb;52(2):333-46.
    doi: 10.1016/j.neuropharm.2006.07.038pubmed: 17045309google scholar: lookup
  78. Tydén E, Tallkvist J, Tjälve H, Larsson P. P-glycoprotein in intestines, liver, kidney and lymphocytes in horse.. J Vet Pharmacol Ther 2009 Apr;32(2):167-76.
    doi: 10.1111/j.1365-2885.2008.01017.xpubmed: 19290947google scholar: lookup
  79. Martinez M, Modric S, Sharkey M, Troutman L, Walker L, Mealey K. The pharmacogenomics of P-glycoprotein and its role in veterinary medicine.. J Vet Pharmacol Ther 2008 Aug;31(4):285-300.
    doi: 10.1111/j.1365-2885.2008.00964.xpubmed: 18638289google scholar: lookup
  80. Mealey KL. Therapeutic implications of the MDR-1 gene.. J Vet Pharmacol Ther 2004 Oct;27(5):257-64.
    doi: 10.1111/j.1365-2885.2004.00607.xpubmed: 15500562google scholar: lookup
  81. Geyer J, Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones.. Curr Pharm Biotechnol 2012 May;13(6):969-86.
    doi: 10.2174/138920112800399301pmc: PMC3419875pubmed: 22039792google scholar: lookup
  82. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications.. Clin Pharmacokinet 2003;42(1):59-98.
    doi: 10.2165/00003088-200342010-00003pubmed: 12489979google scholar: lookup
  83. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernäs H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.. Mol Pharm 2007 Mar-Apr;4(2):252-7.
    doi: 10.1021/mp0600687pubmed: 17263554google scholar: lookup
  84. Ikemura K, Yamamoto M, Miyazaki S, Mizutani H, Iwamoto T, Okuda M. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells.. Mol Pharmacol 2013 Feb;83(2):399-405.
    doi: 10.1124/mol.112.081844pubmed: 23166305google scholar: lookup
  85. Gomes BC, Honrado M, Armada A, Viveiros M, Rueff J, Rodrigues AS. ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance.. Int J Mol Sci 2020 Apr 23;21(8).
    doi: 10.3390/ijms21082985pmc: PMC7215654pubmed: 32340269google scholar: lookup
  86. McKenzie H.C.. Disorders of Foals. Equine Internal Medicine Elsevier; St. Louis, MO, USA: 2018. pp. 1365–1459.
  87. Venner M, Astheimer K, Lämmer M, Giguère S. Efficacy of mass antimicrobial treatment of foals with subclinical pulmonary abscesses associated with Rhodococcus equi.. J Vet Intern Med 2013 Jan-Feb;27(1):171-6.
    doi: 10.1111/jvim.12030pubmed: 23278131google scholar: lookup
  88. Peters J, Block W, Oswald S, Freyer J, Grube M, Kroemer HK, Lämmer M, Lütjohann D, Venner M, Siegmund W. Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals.. Drug Metab Dispos 2011 Sep;39(9):1643-9.
    doi: 10.1124/dmd.111.039206pubmed: 21690264google scholar: lookup
  89. Berlin S, Spieckermann L, Oswald S, Keiser M, Lumpe S, Ullrich A, Grube M, Hasan M, Venner M, Siegmund W. Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals.. Mol Pharm 2016 Mar 7;13(3):1089-99.
    doi: 10.1021/acs.molpharmaceut.5b00907pubmed: 26808255google scholar: lookup
  90. Giguere S., Cohen N.D.. Controversies in therapy of infections caused by Rhodococcus equi in foals. Equine Vet. Educ. 2018;30:336–341.
    doi: 10.1111/eve.12870google scholar: lookup
  91. Hildebrand F, Venner M, Giguère S. Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia.. J Vet Intern Med 2015 Jan;29(1):333-8.
    doi: 10.1111/jvim.12504pmc: PMC4858060pubmed: 25619521google scholar: lookup
  92. Venner M, Credner N, Lämmer M, Giguère S. Comparison of tulathromycin, azithromycin and azithromycin-rifampin for the treatment of mild pneumonia associated with Rhodococcus equi.. Vet Rec 2013 Oct 26;173(16):397.
    doi: 10.1136/vr.101867pubmed: 24106244google scholar: lookup
  93. Peters J, Eggers K, Oswald S, Block W, Lütjohann D, Lämmer M, Venner M, Siegmund W. Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals.. Drug Metab Dispos 2012 Mar;40(3):522-8.
    doi: 10.1124/dmd.111.042267pubmed: 22170330google scholar: lookup
  94. Riesenberg A, Feßler AT, Erol E, Prenger-Berninghoff E, Stamm I, Böse R, Heusinger A, Klarmann D, Werckenthin C, Schwarz S. MICs of 32 antimicrobial agents for Rhodococcus equi isolates of animal origin.. J Antimicrob Chemother 2014 Apr;69(4):1045-9.
    doi: 10.1093/jac/dkt460pubmed: 24275117google scholar: lookup
  95. Gokbulut C, McKellar QA. Anthelmintic drugs used in equine species.. Vet Parasitol 2018 Sep 15;261:27-52.
    doi: 10.1016/j.vetpar.2018.08.002pubmed: 30253849google scholar: lookup
  96. Didier A, Loor F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.. Anticancer Drugs 1996 Sep;7(7):745-51.
    doi: 10.1097/00001813-199609000-00005pubmed: 8949985google scholar: lookup
  97. Olsén L, Ingvast-Larsson C, Bondesson U, Broström H, Tjälve H, Larsson P. Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment.. J Vet Pharmacol Ther 2007 Jun;30(3):194-200.
    doi: 10.1111/j.1365-2885.2007.00850.xpubmed: 17472650google scholar: lookup
  98. Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C, McCracken N. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers.. Eur J Clin Pharmacol 2001 Oct;57(8):571-82.
    doi: 10.1007/s002280100364pubmed: 11758635google scholar: lookup
  99. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.. AAPS J 2015 Jan;17(1):65-82.
    doi: 10.1208/s12248-014-9668-6pmc: PMC4287283pubmed: 25236865google scholar: lookup
  100. Tydén E, Bjornstrom H, Tjälve H, Larsson P. Expression and localization of BCRP, MRP1 and MRP2 in intestines, liver and kidney in horse.. J Vet Pharmacol Ther 2010 Aug;33(4):332-40.
    doi: 10.1111/j.1365-2885.2009.01140.xpubmed: 20646193google scholar: lookup
  101. Ijzer J, Schotanus BA, Vander Borght S, Roskams TA, Kisjes R, Penning LC, Rothuizen J, van den Ingh TS. Characterisation of the hepatic progenitor cell compartment in normal liver and in hepatitis: an immunohistochemical comparison between dog and man.. Vet J 2010 Jun;184(3):308-14.
    doi: 10.1016/j.tvjl.2009.02.016pubmed: 19369099google scholar: lookup
  102. Eldasher LM, Wen X, Little MS, Bircsak KM, Yacovino LL, Aleksunes LM. Hepatic and renal Bcrp transporter expression in mice treated with perfluorooctanoic acid.. Toxicology 2013 Apr 5;306:108-13.
    doi: 10.1016/j.tox.2013.02.009pmc: PMC3645321pubmed: 23435180google scholar: lookup
  103. Vander Borght S, Libbrecht L, Katoonizadeh A, van Pelt J, Cassiman D, Nevens F, Van Lommel A, Petersen BE, Fevery J, Jansen PL, Roskams TA. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences.. J Histochem Cytochem 2006 Sep;54(9):1051-9.
    doi: 10.1369/jhc.5A6912.2006pubmed: 16709727google scholar: lookup
  104. Shimano K, Satake M, Okaya A, Kitanaka J, Kitanaka N, Takemura M, Sakagami M, Terada N, Tsujimura T. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1.. Am J Pathol 2003 Jul;163(1):3-9.
    doi: 10.1016/S0002-9440(10)63624-3pmc: PMC1868160pubmed: 12819005google scholar: lookup
  105. DeNotta SL, Divers TJ. Clinical Pathology in the Adult Sick Horse: The Gastrointestinal System and Liver.. Vet Clin North Am Equine Pract 2020 Apr;36(1):105-120.
    doi: 10.1016/j.cveq.2019.11.004pmc: PMC7127838pubmed: 31982231google scholar: lookup
  106. Hira D, Terada T. BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.. Biochem Pharmacol 2018 Jan;147:201-210.
    doi: 10.1016/j.bcp.2017.10.004pubmed: 29031817google scholar: lookup
  107. Nies AT, Jedlitschky G, König J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain.. Neuroscience 2004;129(2):349-60.
    doi: 10.1016/j.neuroscience.2004.07.051pubmed: 15501592google scholar: lookup
  108. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.. Adv Drug Deliv Rev 2003 Jan 21;55(1):3-29.
    doi: 10.1016/S0169-409X(02)00169-2pubmed: 12535572google scholar: lookup
  109. Keppler D, König J. Hepatic secretion of conjugated drugs and endogenous substances.. Semin Liver Dis 2000;20(3):265-72.
    doi: 10.1055/s-2000-9391pubmed: 11076395google scholar: lookup
  110. Motohashi H, Inui K. Multidrug and toxin extrusion family SLC47: physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K.. Mol Aspects Med 2013 Apr-Jun;34(2-3):661-8.
    doi: 10.1016/j.mam.2012.11.004pubmed: 23506899google scholar: lookup
  111. Gessner A, König J, Fromm MF. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions.. Clin Pharmacol Ther 2019 Jun;105(6):1386-1394.
    doi: 10.1002/cpt.1360pubmed: 30648735google scholar: lookup
  112. Telbisz Á, Homolya L. Recent advances in the exploration of the bile salt export pump (BSEP/ABCB11) function.. Expert Opin Ther Targets 2016;20(4):501-14.
    doi: 10.1517/14728222.2016.1102889pubmed: 26573700google scholar: lookup
  113. Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease.. Semin Liver Dis 2010 May;30(2):125-33.
    doi: 10.1055/s-0030-1253222pmc: PMC3008346pubmed: 20422495google scholar: lookup
  114. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.. Gastroenterology 2002 Nov;123(5):1649-58.
    doi: 10.1053/gast.2002.36591pubmed: 12404239google scholar: lookup
  115. Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.. Clin Pharmacol Ther 2018 Nov;104(5):916-932.
    doi: 10.1002/cpt.1222pmc: PMC6220754pubmed: 30137645google scholar: lookup
  116. Ebrahimi Z, Talaei S, Aghamiri S, Goradel NH, Jafarpour A, Negahdari B. Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.. IET Nanobiotechnol 2020 Aug;14(6):441-448.
    doi: 10.1049/iet-nbt.2019.0351pubmed: 32755952google scholar: lookup
  117. Zhang Y, Walker JB, Minic Z, Liu F, Goshgarian H, Mao G. Transporter protein and drug-conjugated gold nanoparticles capable of bypassing the blood-brain barrier.. Sci Rep 2016 May 16;6:25794.
    doi: 10.1038/srep25794pmc: PMC4867579pubmed: 27180729google scholar: lookup
  118. Chaves C, Campanelli F, Chapy H, Gomez-Zepeda D, Glacial F, Smirnova M, Taghi M, Pallud J, Perrière N, Declèves X, Menet MC, Cisternino S. An Interspecies Molecular and Functional Study of Organic Cation Transporters at the Blood-Brain Barrier: From Rodents to Humans.. Pharmaceutics 2020 Mar 28;12(4).
    doi: 10.3390/pharmaceutics12040308pmc: PMC7238036pubmed: 32231079google scholar: lookup
  119. Braun C, Sakamoto A, Fuchs H, Ishiguro N, Suzuki S, Cui Y, Klinder K, Watanabe M, Terasaki T, Sauer A. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.. Mol Pharm 2017 Oct 2;14(10):3436-3447.
    doi: 10.1021/acs.molpharmaceut.7b00449pubmed: 28880093google scholar: lookup
  120. Talcott P.. Toxicological Problems. Equine Internal Medicine Elsevier; St. Louis, MO, USA: 2018. pp. 1460–1512.
  121. Norman TE, Chaffin MK, Norton PL, Coleman MC, Stoughton WB, Mays T. Concurrent ivermectin and Solanum spp. toxicosis in a herd of horses.. J Vet Intern Med 2012 Nov-Dec;26(6):1439-42.
    doi: 10.1111/j.1939-1676.2012.00996.xpubmed: 22947027google scholar: lookup
  122. Vellonen KS, Hellinen L, Mannermaa E, Ruponen M, Urtti A, Kidron H. Expression, activity and pharmacokinetic impact of ocular transporters.. Adv Drug Deliv Rev 2018 Feb 15;126:3-22.
    doi: 10.1016/j.addr.2017.12.009pubmed: 29248478google scholar: lookup
  123. Niżański W, Levy X, Ochota M, Pasikowska J. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.. Reprod Domest Anim 2014 Jun;49 Suppl 2:8-15.
    doi: 10.1111/rda.12297pubmed: 24947855google scholar: lookup
  124. Miller SR, Cherrington NJ. Transepithelial transport across the blood-testis barrier.. Reproduction 2018 Dec;156(6):R187-R194.
    doi: 10.1530/REP-18-0338pmc: PMC6437009pubmed: 30328342google scholar: lookup
  125. Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S. The Placental Barrier: the Gate and the Fate in Drug Distribution.. Pharm Res 2018 Feb 23;35(4):71.
    doi: 10.1007/s11095-017-2286-0pubmed: 29476301google scholar: lookup
  126. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta.. Placenta 2006 Aug;27(8):861-8.
    doi: 10.1016/j.placenta.2005.09.001pubmed: 16313957google scholar: lookup
  127. Santschi EM, Papich MG. Pharmacokinetics of gentamicin in mares in late pregnancy and early lactation.. J Vet Pharmacol Ther 2000 Dec;23(6):359-63.
    doi: 10.1046/j.1365-2885.2000.00298.xpubmed: 11168913google scholar: lookup
  128. Haritova AM, Krastev SZ, Santos RR, Schrickx JA, Fink-Gremmels J. ABC transporters in the eyes of dogs and implications in drug therapy.. Curr Eye Res 2013 Feb;38(2):271-7.
    doi: 10.3109/02713683.2012.754903pubmed: 23373631google scholar: lookup
  129. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.. Biochim Biophys Acta 1976 Nov 11;455(1):152-62.
    doi: 10.1016/0005-2736(76)90160-7pubmed: 990323google scholar: lookup

Citations

This article has been cited 1 times.
  1. Song Y, Day CM, Afinjuomo F, Tan JE, Page SW, Garg S. Advanced Strategies of Drug Delivery via Oral, Topical, and Parenteral Administration Routes: Where Do Equine Medications Stand?. Pharmaceutics 2023 Jan 4;15(1).
    doi: 10.3390/pharmaceutics15010186pubmed: 36678815google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.